Glioblastoma patients who reached the five-year mark after receiving DCVax-L, an immunotherapy injection co-developed by Dr. Michael Pearlman of HealthOne’s Swedish Medical Center. Pearlman partnered with hospitals in four countries to treat 331 patients, and though the results of the clinical trial might appear disappointing, the doc is thrilled with the outcome. Why? Because the five-year mark currently sits at 6.9 percent, a number that has remained unchanged for decades. DCVax-L delivered the largest increase in survival rates in 20 years, an accomplishment Pearlman says is “simply extraordinary.”
Market Data 
Markets 
AI
